Robert Lutz
Chief Scientific Officer Iksuda Therapeutics
Bob Lutz is a recognized leader in the development of ADCs, with a proven record of advancing breakthrough oncology therapeutics. Since 2015, he has advised biotech and pharma companies worldwide and currently serves as Chief Scientific Officer at Iksuda Therapeutics. Over his 23-year career at ImmunoGen, Inc., he held senior R&D leadership roles, including Vice President of Translational R&D, and played pivotal roles in the development of two FDA-approved ADCs—Kadcyla® and Elahere®.
